ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI…
BYD improves Assisted Driving system in response to Euro NCAPs ATTO 3 grading
LEUVEN, BELGIUM – BYD has responded to the ’Not Recommended’ grading which…
